Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA LE MODIFICHE in fondo alla pagina
Bicocca Open Archive
Background: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 109 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. Objective: To estimate the long-term risk difference for cancer with the immediate ART strategy. Design: Multinational prospective cohort study. Setting: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States. Participants: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016). Measurements: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts < 350 and < 500 × 109 cells/L) ART initiation strategies. Results: During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 × 109 cells/L and less than 350 × 109 cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer. Limitation: Potential residual confounding due to observational study design. Conclusion: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer. Primary Funding Source: Highly Active Antiretroviral Therapy Oversight Committee.
Chammartin, F., Lodi, S., Logan, R., Ryom, L., Mocroft, A., Kirk, O., et al. (2021). Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study. ANNALS OF INTERNAL MEDICINE, 174(6), 768-776 [10.7326/M20-5226].
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study
Chammartin F.;Lodi S.;Logan R.;Ryom L.;Mocroft A.;Kirk O.;D'Arminio Monforte A.;Reiss P.;Phillips A.;El-Sadr W.;Hatleberg C. I.;Pradier C.;Bonnet F.;Law M.;De Wit S.;Sabin C.;Lundgren J. D.;Bucher H. C.
;Calvo G.;Dabis F.;Morfeldt L.;Weber R.;Lind-Thomsen A.;Salbol Brandt R.;Hillebreght M.;Zaheri S.;Wit F. W. N. M.;Scherrer A.;Schoni-Affolter F.;Rickenbach M.;Tavelli A.;Fanti I.;Leleux O.;Mourali J.;Le Marec F.;Boerg E.;Thulin E.;Sundstrom A.;Bartsch G.;Thompsen G.;Necsoi C.;Delforge M.;Fontas E.;Caissotti C.;Dollet K.;Mateu S.;Torres F.;Petoumenos K.;Blance A.;Huang R.;Puhr R.;Gronborg Laut K.;Kristensen D.;Kamara D. A.;Smith C. J.;Raben D.;Matthews C.;Bojesen A.;Grevsen A. L.;Powderly B.;Shortman N.;Moecklinghoff C.;Reilly G.;Smit C.;Ross M.;Fux C. A.;Morlat P.;Friis-Moller N.;Kowalska J.;Bohlius J.;Bower M.;Fatkenheuer G.;Grulich A.;Sjol A.;Meidahl P.;Iversen J. S.;Hillebregt M.;Prins J. M.;Kuijpers T. W.;Scherpbier H. J.;Van Der Meer J. T. M.;Godfried M. H.;Van Der Poll T.;Nellen F. J. B.;Geerlings S. E.;Van Vugt M.;Pajkrt D.;Bos J. C.;Wiersinga W. J.;Van Der Valk M.;Goorhuis A.;Hovius J. W.;Van Eden J.;Henderiks A.;Van Hes A. M. H.;Mutschelknauss M.;Nobel H. E.;Pijnappel F. J. J.;Jurriaans S.;Back N. K. T.;Zaaijer H. L.;Berkhout B.;Cornelissen M. T. E.;Schinkel C. J.;Thomas X. V.;Van Den Berge M.;Stegeman A.;Baas S.;Hage De Looff L.;Versteeg D.;Pronk M. J. H.;Ammerlaan H. S. M.;de Munnik E. S.;Jansz A. R.;Tjhie J.;Wegdam M. C. A.;Deiman B.;Scharnhorst V.;Van Der Plas A.;Weijsenfeld A. M.;Van Der Ende M. E.;de Vries-Sluijs T. E. M. S.;van Gorp E. C. M.;Schurink C. A. M.;Nouwen J. L.;Verbon A.;Rijnders B. J. A.;Bax H. I.;Van Der Feltz M.;Bassant N.;Van Beek J. E. A.;Vriesde M.;Van Zonneveld L. M.;De Oude-Lubbers A.;Van Den Berg-Cameron H. J.;Bruinsma-Broekman F. B.;de Groot J.;De Zeeuw-De Man M.;Boucher C. A. B.;Koopmans M. P. G.;van Kampen J. J. A.;Pas S. D.;Driessen G. J. A.;van Rossum A. M. C.;Van Der Knaap L. C.;Visser E.;Branger J.;Rijkeboer-Mes A.;Duijf-Van De Ven C. J. H. M.;Schippers E. F.;van Nieuwkoop C.;van IJperen J. M.;Geilings J.;van der Hut G.;Franck P. F. H.;Van Eeden A.;Brokking W.;Groot M.;Elsenburg L. J. M.;Damen M.;Kwa I. S.;Groeneveld P. H. P.;Bouwhuis J. W.;Van Den Berg J. F.;Van Hulzen A. G. W.;Van Der Bliek G. L.;Bor P. C. J.;Bloembergen P.;Wolfhagen M. J. H. M.;Ruijs G. J. H. M.;Kroon F. P.;De Boer M. G. J.;Bauer M. P.;Jolink H.;Vollaard A. M.;Dorama W.;Van Holten N.;Claas E. C. J.;Wessels E.;Den Hollander J. G.;Pogany K.;Roukens A.;Kastelijns M.;Smit J. V.;Smit E.;Struik-Kalkman D.;Tearno C.;Bezemer M.;van Niekerk T.;Pontesilli O.;Lowe S. H.;Oude Lashof A. M. L.;Posthouwer D.;Ackens R. P.;Schippers J.;Vergoossen R.;Weijenberg-Maes B.;van Loo I. H. M.;Havenith T. R. A.;Leyten E. M. S.;Gelinck L. B. S.;van Hartingsveld A.;Meerkerk C.;Wildenbeest G. S.;Mutsaers J. A. E. M.;Jansen C. L.;Mulder J. W.;Vrouenraets S. M. E.;Lauw F. N.;van Broekhuizen M. C.;Paap H.;Vlasblom D. J.;Smits P. H. M.;Weijer S.;El Moussaoui R.;Bosma A. S.;van Vonderen M. G. A.;van Houte D. P. F.;Kampschreur L. M.;Dijkstra K.;Faber S.;Weel J.;Kootstra G. J.;Delsing C. E.;van der Burg-Van de Plas M.;Heins H.;Lucas E.;Kortmann W.;van Twillert G.;Cohen Stuart J. W. T.;Diederen B. M. W.;van Truijen-Oud F. A.;van der Reijden W. A.;Jansen R.;Brinkman K.;van den Berk G. E. L.;Blok W. L.;Frissen P. H. J.;Lettinga K. D.;Schouten W. E. M.;Veenstra J.;Brouwer J. C.;Geerders F. G.;Hoeksema K.;Kleene J. M.;van der Meche B. I.;Spelbrink M.;Sulman H.;Toonen A. J. M.;Wijnands S.;Kwa D.;Witte E.;Koopmans P. P.;Keuter M.;van der Ven A. J. A. M.;ter Hofstede H. J. M.;Dofferhoff A. S. M.;van Crevel R.;Albers M.;Bosch M. E. W.;Grintjes-Huisman K. J. T.;Zomer J. B.;Stelma F. F.;Rahamat-Langendoen J.;Burger D.;Richter C.;Gisolf H. E.;Hassing J. R.;ter Beest G.;van Bentum P. H. M.;Langebeek N.;Tiemessen R.;Swanink C. M. A.;van Lelyveld S. F. L.;Soetekouw R.;Hulshoff N.;van der Prijt L. M. M.;van der Swaluw J.;Bermon N.;Herpers B. L.;Veenendaal D.;Verhagen W. D. M.;van Wijk M.;van Kasteren M. E. E.;Brouwer E. A.;de Kruijf-Van de Wiel B. A. F. M.;Kuipers M.;Santegoets R. M. W. J.;van der Ven B.;Marcelis H. J.;Buiting A. G. M.;Kabel J. P.;Bierman W. F. W.;Scholvinck H.;Wilting R. K.;Stienstra Y.;de Groot-De Jonge H.;van der Meulen A. P.;de Weerd A. D.;Ludwig-Roukema J.;Niesters H. G. M.;Riezebos-Brilman A.;van Leer-Buter C. C.;Knoester M.;Hoepelman A. I. M.;Mudrikova T.;Ellerbroek M. P.;Oosterheert J. J.;Arends E. J.;Barth E. R.;Wassenberg M. W. M.;Schadd M. E.;van Elst-Laurijssen D. H. M.;van Oers-Hazelzet B. E.;Vervoort S.;van Berkel M.;Schuurman R.;Verduyn-Lunel F.;Wensing A. M. J.;Peters E. J. G.;van Agtmael A. M.;Bomers M.;de Vocht J.;Heitmuller M.;Laan M. L.;Pettersson M. A.;Vandenbroucke-Grauls C. M. J. E.;Ang W. C.;Geelen S. P. M.;Wolfs T. F. W.;Bont J. L.;Nauta N.;Bezemer O. D.;van Sighem I. A.;Boender S. T.;de Jong A.;Bergsma D.;Hoekstra P.;de Lang A.;Grivell S.;Jansen A.;Rademaker J. M.;Raethke M.;Meijering R.;Schnorr S.;de Groot L.;van den Akker M.;Bakker Y.;Claessen E.;El Berkaoui A.;Koops J.;Kruijne E.;Lodewijk C.;Munjishvili L.;Peeck B.;Ree C.;Regtop R.;Ruijs Y.;Rutkens T.;van de Sande L.;Schoorl M.;Timmerman A.;Tuijn E.;Veenenberg L.;van der Vliet S.;Wisse A.;Woudstra T.;Tuk B.;Dupon M.;Gaborieau V.;Lacoste D.;Malvy D.;Mercie P.;Neau D.;Pellegrin L. J.;Tchamgoue S.;Lazaro E.;Cazanave C.;Vandenhende M.;Vareil O. M.;Gerard Y.;Blanco P.;Bouchet S.;Breilh D.;Fleury H.;Pellegrin I.;Chene G.;Thiebaut R.;Wittkop L.;Lawson-Ayayi S.;Gimbert A.;Desjardin S.;Lacaze-Buzy L.;Petrov-Sanchez V.;Andre N.;Bernard K.;Caubet O.;Caunegre L.;Chossat I.;Courtault C.;Dauchy A. F.;Dondia D.;Duffau P.;Dutronc H.;Farbos S.;Faure I.;Ferrand H.;Greib C.;Hessamfar M.;Imbert Y.;Lataste P.;Marie J.;Mechain M.;Monlun E.;Ochoa A.;Pistone T.;Raymond I.;Receveur C. M.;Rispal P.;Sorin L.;Valette C.;Viallard J. F.;Wille H.;Wirth G.;Lafon M.;Trimoulet P.;Bellecave P.;Tumiotto C.;Haramburu F.;Miremeont-Salame G.;Blaizeau J. M.;Decoin M.;Hannapier C.;Lenaud E.;Pougetoux A.;Delveaux S.;D'Ivernois C.;Diarra F.;Uwamaliya-Nziyumvira B.;Palmer G.;Conte V.;Sapparrart V.;Moore R.;Edwards S.;Hoy J.;Watson K.;Roth N.;Lau H.;Bloch M.;Baker D.;Carr A.;Cooper D.;O'Sullivan M.;Nolan D.;Guelfi G.;Domingo P.;Sambeat A. M.;Gatell J.;Del Cacho E.;Cadafalch J.;Fuster M.;Codina C.;Sirera G.;Vaque A.;Delforge M.;Clumeck N.;Gennotte F. A.;Gerard M.;Kabeya K.;Konopnicki D.;Libois A.;Martin C.;Payen C. M.;Semaille P.;Van Laethem Y.;Neaton J.;El-Sadr M. W.;Krum E.;Thompson G.;Wentworth D.;Luskin-Hawk R.;Telzak E.;Abrams I. D.;Cohn D.;Markowitz N.;Arduino R.;Mushatt D.;Friedland G.;Perez G.;Tedaldi E.;Fisher E.;Gordin F.;Crane R. L.;Sampson J.;Baxter J.;Gazzard B.;Horban A.;Karpov I.;Pedersen C.;Ristola M.;Rockstroh J.;Peters L.;Fischer H. A.;Larsen F. J.;Podlekareva D.;Cozzi-Lepri A.;Shepherd L.;Schultze A.;Amele S.;Losso M.;Kundro M.;Schmied B.;Zangerle R.;Vassilenko A.;Mitsura M. V.;Paduto D.;Florence E.;Vandekerckhove L.;Hadziosmanovic V.;Begovac J.;Machala L.;Jilich D.;Sedlacek D.;Kronborg G.;Benfield T.;Gerstoft J.;Katzenstein T.;Moller F. N.;Ostergaard L.;Wiese L.;Nielsen N. L.;Zilmer K.;Smidt J.;Aho I.;Viard J. P.;Girard P. M.;Duvivier C.;Schmidt R.;Degen O.;Stellbrink J. H.;Stefan C.;Bogner J.;Fatkenheuer G.;Chkhartishvili N.;Gargalianos P.;Xylomenos G.;Armenis K.;Sambatakou H.;Szlavik J.;Gottfredsson M.;Mulcahy F.;Yust I.;Turner D.;Burke M.;Shahar E.;Hassoun G.;Elinav H.;Haouzi M.;Elbirt D.;Sthoeger M. Z.;Esposito R.;Mazeu I.;Mussini C.;Mazzotta F.;Gabbuti A.;Vullo V.;Lichtner M.;Zaccarelli M.;Antinori A.;Acinapura R.;Plazzi M.;Lazzarin A.;Castagna A.;Gianotti N.;Galli M.;Ridolfo A.;Rozentale B.;Uzdaviniene V.;Matulionyte R.;Staub T.;Hemmer R.;Ormaasen V.;Maeland A.;Bruun J.;Knysz B.;Gasiorowski J.;Inglot M.;Bakowska E.;Flisiak R.;Grzeszczuk A.;Parczewski M.;Maciejewska K.;Aksak-Was B.;Beniowski M.;Mularska E.;Smiatacz T.;Gensing M.;Jablonowska E.;Malolepsza E.;Wojcik K.;Mozer-Lisewska I.;Caldeira L.;Mansinho K.;Maltez F.;Radoi R.;Oprea C.;Panteleev A.;Panteleev O.;Yakovlev A.;Trofimora T.;Khromova I.;Kuzovatova E.;Borodulina E.;Vdoushkina E.;Jevtovic D.;Tomazic J.;Miro M. J.;Moreno S.;Rodriguez J. M.;Clotet B.;Jou A.;Paredes R.;Tural C.;Puig J.;Bravo I.;Gutierrez M.;Mateo G.;Laporte M. J.;Falconer K.;Thalme A.;Sonnerborg A.;Blaxhult A.;Flamholc L.;Cavassini M.;Calmy A.;Furrer H.;Battegay M.;Schmid P.;Kuznetsova A.;Kyselyova G.;Sluzhynska M.;Johnson A. M.;Simons E.;Orkin C.;Weber J.;Scullard G.;Clarke A.;Leen C.;Thulin G.;Sundstrom A.;Akerlund B.;Koppel K.;Karlsson A.;Hakangard C.;Castelli F.;Cauda R.;Di Perri G.;Iardino R.;Ippolito G.;Marchetti C. G.;Perno F. C.;von Schloesser F.;Viale P.;Antinori A.;Ceccherini-Silberstein F.;Girardi E.;Lo Caputo S.;Puoti M.;Andreoni M.;Ammassari A.;Balotta C.;Bandera A.;Bonfanti P.;Bonora S.;Borderi M.;Calcagno A.;Calza L.;Capobianchi R. M.;Cingolani A.;Cinque P.;De Luca A.;Di Biagio A.;Gori A.;Guaraldi G.;Lapadula G.;Madeddu G.;Maggiolo F.;Marcotullio S.;Monno L.;Nozza S.;Quiros Roldan E.;Rossotti R.;Rusconi S.;Santoro M. M.;Saracino A.;Galli L.;Lorenzini P.;Rodano A.;Shanyinde M.;Carletti F.;Carrara S.;Di Caro A.;Graziano S.;Petrone F.;Prota G.;Quartu S.;Truffa S.;Giacometti A.;Costantini A.;Barocci V.;Angarano G.;Santoro C.;Suardi C.;Donati V.;Verucchi G.;Minardi C.;Quirino T.;Abeli C.;Manconi E. P.;Piano P.;Cacopardo B.;Celesia B.;Vecchiet J.;Falasca K.;Pan A.;Lorenzotti S.;Sighinolfi L.;Segala D.;Vichi F.;Cassola G.;Viscoli C.;Alessandrini A.;Bobbio N.;Mazzarello G.;Mastroianni C.;Belvisi V.;Caramma I.;Chiodera A.;Milini P.;Rizzardini G.;Moioli C. M.;Piolini R.;Ridolfo L. A.;Salpietro S.;Tincati C.;Puzzolante C.;Abrescia N.;Chirianni A.;Borgia G.;Orlando R.;Bonadies G.;Di Martino F.;Gentile I.;Maddaloni L.;Cattelan M. A.;Marinello S.;Cascio A.;Colomba C.;Baldelli F.;Schiaroli E.;Parruti G.;Sozio F.;Magnani G.;Ursitti A. M.;Cristaudo A.;Baldin G.;Capozzi M.;Cicalini S.;Fontanelli Sulekova L.;Iaiani G.;Latini A.;Mastrorosa I.;Savinelli S.;Vergori A.;Cecchetto M.;Viviani F.;Bagella P.;Rossetti B.;Franco A.;Fontana Del Vecchio R.;Francisci D.;Di Giuli C.;Caramello P.;Orofino C. G.;Sciandra M.;Bassetti M.;Londero A.;Pellizzer G.;Manfrin V.;Starnini G.;Ialungo A.;Dellamonica P.;Bernard E.;Courjon J.;Cua E.;De Salvador-Guillouet F.;Durant J.;Etienne C.;Ferrando S.;Mondain-Miton V.;Naqvi A.;Perbost I.;Pillet S.;Prouvost-Keller B.;Pugliese P.;Rio V.;Risso K.;Roger M. P.;Aubert V.;Bernasconi E.;Ciuffi A.;Dollenmaier G.;Egger M.;Elzi L.;Fehr J.;Fellay J.;Gunthard F. H.;Haerry D.;Hasse B.;Hirsch H. H.;Hoffmann M.;Hosli I.;Kahlert C.;Kaiser L.;Keiser O.;Klimkait T.;Kouyos D. R.;Kovari H.;Ledergerber B.;Martinetti G.;Martinez de Tejada B.;Marzolini C.;Metzner J. K.;Muller N.;Nicca D.;Pantaleo G.;Paioni P.;Rauch A.;Rudin C.;Speck R.;Stockle M.;Tarr P.;Trkola A.;Vernazza P.;Wandeler G.;Yerly S.
2021
Abstract
Background: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 109 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. Objective: To estimate the long-term risk difference for cancer with the immediate ART strategy. Design: Multinational prospective cohort study. Setting: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States. Participants: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016). Measurements: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts < 350 and < 500 × 109 cells/L) ART initiation strategies. Results: During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 × 109 cells/L and less than 350 × 109 cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer. Limitation: Potential residual confounding due to observational study design. Conclusion: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer. Primary Funding Source: Highly Active Antiretroviral Therapy Oversight Committee.
Chammartin, F., Lodi, S., Logan, R., Ryom, L., Mocroft, A., Kirk, O., et al. (2021). Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study. ANNALS OF INTERNAL MEDICINE, 174(6), 768-776 [10.7326/M20-5226].
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/352662
Citazioni
15
15
Social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 598/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
